Calculating a value

Trying to determine the relative acquisition value of top-tier biotech is a tricky exercise, depending on the acquirer's need for sales leverage versus pipeline enhancement.

In many cases, too, it is apparent that the market puts more value on a biotech company's R&D prospects than might a pharma company focused on sales flow, which could affect the premium expected by biotech shareholders under any proposed takeout.